Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
Claudia Palacio-Pastrana,1 Eduardo Chávez-Mondragón,2 Abraham Soto-Gómez,3 Rubén Suárez-Velasco,4 Miguel Montes-Salcedo,5 Lourdes Fernández de Ortega,6 Linda Nasser-Nasser,7 Leopoldo Baiza-Durán,8 Oscar Olvera-Monta&nti...
Enregistré dans:
Auteurs principaux: | Palacio-Pastrana C, Chávez-Mondragón E, Soto-Gómez A, Suárez-Velasco R, Montes-Salcedo M, Fernández de Ortega L, Nasser-Nasser L, Baiza-Durán L, Olvera-Montaño O, Muñoz-Villegas P |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e872e9bd32b943f6bf9478ac1b9374eb |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
par: Katelin Quantz, et autres
Publié: (2021) -
Topical Difluprednate for Early Corneal Graft Rejection After Penetrating Keratoplasty
par: Said OM, et autres
Publié: (2020) -
A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05%
par: Kusne Y, et autres
Publié: (2016) -
Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
par: William Stringer, et autres
Publié: (2010) -
Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary
par: Vivian Laquer, MD, et autres
Publié: (2022)